News-Medical.Net on MSN

Short-duration psychedelic therapy shows promise for major depression treatment

By Tarun Sai Lomte A controlled clinical trial suggests a fast-acting psychedelic approach may reduce depressive symptoms, but researchers stress careful interpretation and the need for larger ...
European Medical Journal

Major Depressive Disorder Shares Immune Signature with AD

Major depressive disorder is linked to Th2 immune dysregulation similar to atopic dermatitis. Could dupilumab offer a new ...
Seeking Alpha

BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD)

BURLINGTON, Mass. and JERUSALEM, June 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (BWAY) (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health ...
GEN

AbbVie Embraces Psychedelic Drug with Up-to-$1.2B Deal for Gilgamesh’s MDD Candidate

AbbVie has agreed to acquire Gilgamesh Pharmaceuticals’ lead pipeline asset bretisilocin, a clinical-stage candidate designed to treat moderate-to-severe major depressive disorder (MDD), for up to ...